share_log

Allarity Therapeutics | 8-K: Current report

Allarity Therapeutics | 8-K: Current report

Allarity Therapeutics | 8-K:重大事件
美股SEC公告 ·  06/06 08:56

Moomoo AI 已提取核心訊息

Allarity Therapeutics, Inc. has reported a significant change in its executive management structure through a filing with the SEC. The company, based in Delaware and listed under the ticker ALLR on the Nasdaq Stock Market, disclosed the replacement of a consultancy agreement with a new Management Services Agreement (MSA) with Ljungaskog Consulting AB, effective June 1, 2024. This new agreement engages Thomas H. Jensen, the CEO of Allarity Therapeutics, to continue his services with a fixed monthly fee of $43,750 and a one-time signing bonus of $100,000. The MSA outlines performance-based compensation adjustments, eligibility for annual discretionary performance bonuses, and expense reimbursements. It also details termination provisions for both the company and the consultant, including termination for convenience and for cause, with specific financial implications. The MSA supersedes the previous consultancy agreement and is set to continue until the agreed termination conditions are met. The full text of the MSA is included as Exhibit 10.1 in the SEC filing.
Allarity Therapeutics, Inc. has reported a significant change in its executive management structure through a filing with the SEC. The company, based in Delaware and listed under the ticker ALLR on the Nasdaq Stock Market, disclosed the replacement of a consultancy agreement with a new Management Services Agreement (MSA) with Ljungaskog Consulting AB, effective June 1, 2024. This new agreement engages Thomas H. Jensen, the CEO of Allarity Therapeutics, to continue his services with a fixed monthly fee of $43,750 and a one-time signing bonus of $100,000. The MSA outlines performance-based compensation adjustments, eligibility for annual discretionary performance bonuses, and expense reimbursements. It also details termination provisions for both the company and the consultant, including termination for convenience and for cause, with specific financial implications. The MSA supersedes the previous consultancy agreement and is set to continue until the agreed termination conditions are met. The full text of the MSA is included as Exhibit 10.1 in the SEC filing.
Allarity Therapeutics,Inc.通過向SEC提交文件彙報了其高管管理結構的重大變化。該公司總部位於特拉華州,股票代碼爲納斯達克股票市場的ALLR,披露了廢除諮詢協議並簽署了與Ljungaskog Consulting AB的新管理服務協議(MSA),自2024年6月1日起生效。這份新協議讓Allarity Therapeutics的CEO Thomas H.Jensen以固定月薪43,750美元和一次性簽字獎金10萬美元的價格繼續提供服務。MSA概述了基於績效的薪酬調整、年度自主績效獎金的資格和費用報銷。它還詳細說明了公司和諮詢師的終止條款,包括出於方便和因故終止,並具有具體的財務影響。MSA取代了以前的諮詢協議,並將繼續執行,直到達成協議的終止條件。SEC文件中的附件10.1包含了MSA的全文。
Allarity Therapeutics,Inc.通過向SEC提交文件彙報了其高管管理結構的重大變化。該公司總部位於特拉華州,股票代碼爲納斯達克股票市場的ALLR,披露了廢除諮詢協議並簽署了與Ljungaskog Consulting AB的新管理服務協議(MSA),自2024年6月1日起生效。這份新協議讓Allarity Therapeutics的CEO Thomas H.Jensen以固定月薪43,750美元和一次性簽字獎金10萬美元的價格繼續提供服務。MSA概述了基於績效的薪酬調整、年度自主績效獎金的資格和費用報銷。它還詳細說明了公司和諮詢師的終止條款,包括出於方便和因故終止,並具有具體的財務影響。MSA取代了以前的諮詢協議,並將繼續執行,直到達成協議的終止條件。SEC文件中的附件10.1包含了MSA的全文。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息